MAPT and early-onset autosomal dominant Alzheimer disease: Our rational design of multifunctional therapeutic agent that simultaneously targets tau misfolding process, copper dyshomeostasis, and oxidative stress of reactive oxygen species, may hold considerable implications for the treatment of Alzheimer’s disease.